Friday, May 27th, 2022

THEME:

Prevention and Treatment of Substance Use Disorders:
Progress and Prospects for Psychedelic Science

Master of Ceremonies: Stacia Butterfield

8:15 am – 9:00 am

Conference Opening

  • Land acknowledgement: Dr. Brian Rush, CAMH and Dalla Lana School of Public Health, University of Toronto
  • Opening Prayer and Song from Walter Lindstone, Batchewana First Nation Anishinaabe and CAMH (Shkaabe Makwa)
  • Brief Welcome from Planning Committee (Drs. Dominique Morisano, Brian Rush, Monnica Williams, Doris Payer, Sukhpreet Klaire, Thomas Babor, and Mary Bartram)
  • Welcome from host institutions (CAMH, CCSA, MHCC)
  • Remarks by Nathaniel Erskine-Smith, Member of Parliament, Beaches-East York
  • Day 1 Master of Ceremonies: Stacia Butterfield

9:00 am – 9:50 am

Keynote Presentation #1

Historical and recent advances in psychedelic science, neuroscience and clinical contributions to substance use and addictions

  • Dr David Nutt; Imperial College London, Awakn Life Sciences
  • Discussant: Dr Sukhpreet Klaire, University of British Columbia

9:50 am – 10:00 am

Keynote Presentation Q and A

10:00 am – 10:30 am

Break

10:30 am – 11:45 am

Peer-Reviewed Paper presentations

Peer-Reviewed Paper presentations focused on neuroscience/clinical findings in substance use/addictions (4 of 15 minutes)

ID-25

Abstract

The impact of ineffective placebo control in microdosing trials

Authors

  • Dr. Balazs Szigeti, Imperial College London;1
  • Dr. Robin Carhart-Harris, University of California, San Francisco;
  • Dr. David Erritzoe, Imperial College London

ID-8

Abstract

MDMA Therapy for the Treatment of Alcohol Use Disorder: The Results of the World’s First Study - And Plans for Ongoing Further Research.

Authors

  • Dr. Ben Sessa, Imperial College London

ID-11

Abstract

Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice

Authors

  • Dr. Elizabeth Nielson, Fluence

ID-65

Abstract

The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity

Authors

  • Peter Bedford, Centre for Addiction and Mental Health;
  • Daniel Hauke, University of Basel;
  • Zheng Wang, Centre for Addiction and Mental Health;
  • Dr. Volker Roth, University of Basel;
  • Monika Nagy-Huber, University of Basel;
  • Friederike Holze, University of Basel;
  • Laura Ley, Departement Biomedizin, University of Basel;
  • Dr. Patrick Vizeli, Departement Biomedizin, University of Basel;
  • Dr. Matthias Liechti, University of Basel;
  • Dr. Stefan Borgward, University of Basel;
  • Dr. Felix Müller, University Psychiatric Clinics Basel;
  • Dr. Andreea Diaconescu, Centre for Addiction and Mental Health

*The presenting author is underlined.

11:45 am – 12:45 pm

Lunch (onsite, included)

12:45 pm – 1:35 pm

Keynote Presentation #2

Traditional medicine, culture and psychedelic science: Healing for substance use and addictions

  • Dr. Anja Loizaga-Velder, Nierika Institute for Intercultural Medicine
  • Discussant: Dr. Olivia Marcus, New York University 

1:35 pm – 1:45 pm

Keynote Presentation Q and A

1:45 pm – 3:15 pm

Peer-Reviewed Paper presentations

Peer-Reviewed Paper Presentations focused on traditional approaches to substance use/addictions (5 of 15 minutes)

ID-47

Abstract

Naturalistic Psychedelic use Among Indigenous Peoples to Alleviate Racial Trauma

Authors

  • Sara de la Salle, University of Ottawa;
  • Sophia Gran-Ruaz, University of Ottawa;
  • Dr. Dawn Davis, NativeSci;
  • Dr. Monnica Williams, University of Ottawa;
  • Dr. Alan Davis, Ohio State University

ID-22

Abstract

Integrating Anthropological Knowledge into Psychedelic Spiritual Care: How Indigenous
Wisdom and Ayahuasca Religions can inform Best Practice

Authors

  • Dr. Marc Blainey, Homewood Health Centre

ID-114

Abstract

Preliminary results from the Ayahuasca Treatment Outcome Project (ATOP): Takiwasi Center Peru.

Authors

  • Dr. Brian Rush, Centre for Addiction and Mental Health, University of Toronto
  • Dr. Olivia Marcus, New York University
  • Sara Garcia, Takiwasi Centre, Peru
  • Dr. Anja Loizaga-Velder, Nierika Institute, National Autonomous University of Mexico, Mexico
  • Gabriel Loewinger, Harvard University School of Public Health
  • Ariane Spitalier, Autonomous University of Barcelona,  Spain
  • Dr. Fernando Mendive, Takiwasi Centre, Peru

ID-28

Abstract

Persisting Effects of Ayahuasca on Empathy, Creative Thinking, Decentering, Personality, and Well-Being

Authors

  • Maggie Kiraga;
  • Dr. Natasha Mason, Maastricht University;
  • Dr. Malin Uthaug, Maastricht University;
  • Dr. Kim van Oorsouw, Maastricht University;
  • Dr. Stefan Toennes, University of Frankfurt;
  • Dr. Johannes Ramaekers, Maastricht University;
  • Dr. Kim Kuypers, Maastricht University

3:15 pm – 3:45 pm

Break

3:45 pm – 5:15 pm

Peer-Reviewed Paper presentations

Peer-Reviewed Paper Presentations focused on policy, public health, and regulatory issues in substance use and addictions (5 of 15 minutes)

ID-46

Abstract

Psychedelics for addiction treatment: enabling access and protecting innovation and opportunity through preserving the public domain

Authors

  • Shahin Shams, Porta Sophia;
  • Dr Sisi Li, Porta Sophia;
  • Amanda Pratt, Holtz Center for Science and Technology Studies;
  • Dr. David Casimir, Casimir Jones S.C.;
  • Dr. Thomas Isenbarger, Casimir Jones S.C.

ID-50

Abstract

From Policy to Practice, Practice to Policy (P2P): An Interdisciplinary and Practice Based Approach to Ketamine Assisted Therapy Policy Development in Canada

Authors

  • Dr. Anthony Barale, The Ketamine Assisted Therapy Association of Canada;
  • Dr. Ian Mitchell, Royal Inland Hospital;
  • Dr. Joel Kailia, The Ketamine Assisted Therapy Association of Canada;
  • Madison Nobbs, Ketamine Assisted Therapy Association of Canada;
  • Dr. Neil Hanon, Ketamine Assisted Therapy Association of Canada;
  • Dr. Sukh Dhiman, The Ketamine Assisted Therapy Association of Canada

ID-118

Abstract

The future of psychedelic therapies in health system stewardship

Authors

  • Dr. Kenneth Tupper, University of British Columbia

ID-5

Abstract

The Canadian Psychedelic Survey; A Cross-Sectional Survey of Psychedelic Use in Canada

Authors

  • Dr. Philippe Lucas, Sabi Mind

5:15 pm – 5:30 pm

Break

5:30 pm - 6:30 pm

Evening Panel

Policy, public health, and regulatory issues: Setting the research agenda for psychedelic-assisted therapies for substance use disorders

What are the steps for developing new treatment pathways for substance use disorders with psychedelic-assisted therapies including key research questions, regulatory issues, risk assessment, potential concerns or benefits, etc.

  • Dr. Ken Tupper, University of British Columbia, Canada
  • Ifetayo Harvey, POC Psychedelic Collective, USA
  • Dr. Gady Zabicky Sirot, Mexican CONADIC National Council on Addictions, Mexico
  • Dr. Ben Sessa, Imperial College London and Awakn Life Sciences, UK
  • Dr. Anja Loizaga-Velder, Nierika Institute for Intercultural Medicine, Mexico
  • Moderator: Dr. Dominique Morisano, University of Toronto/University of Ottawa/CAMH

8:00 pm – 9:30 pm

Networking Social Event

Saturday, May 28th, 2022

THEME:

Prevention and Treatment of Mental Health Disorders:
Part I: Neuroscience/ Clinical Applications; Traditional Medicine/Cultural Considerations

Master of Ceremonies: Mary Sanders

8:45 am – 9:00 am

Opening Remarks and Working Documentary Sneak Peak: Transcendence produced by A Colorful World and directed by Esteban Serrano

9:00 am - 9:50 am

Keynote Presentation #3

Psychedelics and Racial Justice

  • Dr. Monnica Williams, School of Psychology, University of Ottawa
  • Discussant: Victor Cabral, Fluence and American Psychedelic Practitioners Association

9:50 am – 10:00 am

Keynote Presentation Q and A

10:00 am – 10:45 am

Poster Viewing and Refreshment Break

ID

Poster Title

Presenter

124

A Matter of Context: A Comparative Study of Generational Media and its Impact on Psychedelic Policy and Regulations

Michael Kydd

86

A vision for psychedelic research in Canada

Scott Bernstein

19

Analysis of the brain’s energy landscape dynamics during psilocybin and escitalopram treatment for depression

Parker Singleton

LB204

Ayahuasca Awakening A Guide to Self-Discovery Self-Mastery and Self-Care

Jessica Rochester

79

Behavioural Investigations of Psilocybin in Animals, A Scoping Review

Ron Shore

110

Creating an Intercollegiate Psychedelics Network: Student Empowerment with a Global Reach

Joel Lopez

82

Does psilocybin change synaptic density in the brains of patients with mild cognitive impairment? A double-blind placebo-controlled study design

Jianmeng Song

54

Experiences of Psychedelic Use Among Individuals with Psychotic Symptoms

Jade Gallo

32

Functional connectivity during a personalized trauma audio task is altered after MDMA-assisted psychotherapy in PTSD patients and correlates with recovery

Parker Singleton

LB207

Ketamine and psilocybin differentially impact top-down predictions during the mismatch negativity: An EEG Study

Shona Allohverdi

LB203

Looking through the doors of perception: the past, present and future of psychedelics to treat addiction

Rayyan Zafar

80

Mushrooms, madness, media: a content analysis of Canadian news media and how it frames the relationship between psilocybin and violence.

David Kryszajtys

9

Neural correlates of anti-suiciDal rEsponse to kEtamine in treatment resistant biPolar dePression (DEEPP-Study). Opel Label Pilot Clinical Trial

Yuliya Knyahnytska

115

Neurobiological Effects of Psilocybin in  Treatment Resistant Bipolar Depression: A Protocol for An Emotional-Processing fMRI Pilot Study

Joshua Rosenblat

14

Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics

Lily Aleksandrova

68

Patterns of Hallucinogen Use Prior to First Admission to Inpatient Psychiatry in Ontario, Canada between 2006 and 2020

Judy Castañeda

67

Pharmacological and Pharmacokinetic Profile of CYB003, a Novel, Orally Active Analog of Psilocybin

Geoff Varty

99

Point of Departure: Training & the Psychedelic Therapeutic Paradigm

Anne Vallely

121

Preliminary Evidence that a Reduction in Racial Trauma Symptoms Mediates the Association between Acute Psychedelic Effects and Reduced Alcohol Use among People of Color in the United States and Canada

Angela Haeny

117

Psilocybin's mechanism of action in the treatment of depression

Brandon Chai

21

Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian Setting

Elena Argento

95

Psychedelic use, mental health, and suicidality in Canadian university students

Julia Pei

89

Research Abuses Against People of Colour in Early Psychedelic Research and Implications for Psychedelic Research, Therapy, and Policy

Dana Strauss

55

Serotonergic Psychedelic Drugs Dynamically Reconfigure Brain Network Organization

Manesh Girn

126

The Controlled Substances Act Regulations on Schedule I Researcher Registrations and the Investigation of Hallucinogenic Substances

Theresa Carbonaro

36

The effect of psilocybin therapy for depression on low-frequency brain activity in response to music

Natalie Ertl

43

The effects of psilocybin-induced glucocorticoid release on post-acute and delayed anxiolysis in mice

CODY WENTHUR

61

The use of psychedelic substances for smoking cessation: A systematic review

Arina Bogdan

49

Therapeutic Intent and Caregiver Communication in Psychedelic Medicine

Lucas Standing

90

Will Psychedelic-Assisted Therapies Benefit from COVID-19 Pharmaceutical Regulatory Modernization?  The Future of ‘Alternative’ Therapies in Canada

Agnieszka Doll









10:45 am – 12:15 pm

Peer-Reviewed Paper presentations

Peer-Reviewed Paper presentations focused on neuroscience/clinical findings (5 of 15 minutes)

ID-81

Abstract

Ketamine-Assisted  and Psilocybin-Assisted Therapies, delivered within a Community of Practice Framework: Operations and Outcomes of the Roots to Thrive model

Authors

  • Shannon Dames, Vancouver Island University;
  • Pamela Kryskow, Vancouver Island University

ID-78

Abstract

The Effects of Psilocybin on Cognitive and Neural Flexibility: The Limits of Excessive Flexing

Authors

  • Dr. Manoj Doss, Johns Hopkins University School of Medicine

ID-93

Abstract

Psychedelic microdosers report therapeutic motivations and longitudinal improvements in mood, mental health and psychomotor functioning relative to non-microdosing comparators

Authors

  • Joseph Rootman, UBC Okanagan;
  • Dr. Pamela Kryskow, Vancouver Island University;
  • Dr. Maggie Kiraga;
  • Paul Stamets;
  • Kalin Harvey, Quantified Citizen;
  • Eesmyal Santos-Brault, Quantified Citizen;
  • Dr. Kim Kuypers, Maastricht University;
  • Dr. Zach Walsh, University of British Columbia – Okanagan

ID-106

Abstract

A False Renaissance: The story of the first mainstream psychedelic

Authors

  • Dr. Elias Dakwar, Columbia University

ID-75

Abstract

Trial of Psilocybin versus Escitalopram for Depression; 6 months follow-up data

Authors

  • Dr. David Erritzoe, Imperial College London;
  • Dr. Rosalind Watts, Twelve Trees Integration Ltd;
  • Bruna Giribaldi, Imperial College London;
  • Balazs Szigeti, Imperial College London;
  • Dr. Fernando Rosas, Imperial College London;
  • Dr. David Nutt, Imperial College London;
  • Dr. Robin Carhart-Harris, University of California, San Francisco

12:15 pm – 1:15 pm

Lunch (onsite, included)

1:15 pm – 2:45 pm

Peer-Reviewed Paper presentations

Peer-Reviewed Paper Presentations focused on Traditional approaches (5 of 15 minutes)

ID-51

Abstract

Revolution or an endless cycle? The epistemic and ethical concerns of psychedelic psychiatry

Authors

  • Dr. Olivia Marcus, New York University

ID-63

Abstract

Psychedelic Medicine and Muslim Communities: From Sufism to the Modern Era

Authors

  • Dr. Manzarsadat Zareashkezari, University of Ottawa

ID-29

Abstract

Exploring experiences and perceptions around purging during Ayahuasca rituals: a qualitative study at a drug rehabilitation center in Peru

Authors

  • Svĕt Lustig Vijay, London School of Tropical Hygiene and Medicine;
  • Fabio Friso, Center for the Rehabilitation of Drug Addicts and Research on Traditional Medicines;
  • Dr. Magdalena Harris, Department of Public Health, Environments and Society, London School of Tropical Hygiene and Medicine;
  • Dr. Matteo Politi, Center for the Rehabilitation of Drug Addicts and Research on Traditional Medicines

ID-96

Abstract

Culturally-Safe PsychedelicAssisted Psychotherapy: A Foundation for Training Programs

Authors

  • Tatiana Sanchez, University of British Columbia - Okanagan;
  • Sarah Daniels, University of British Columbia - Okanagan;
  • Michelle St. Pierre, The University of British Columbia;
  • Joseph Rootman, UBC Okanagan;
  • Christopher Nelson, University of British Columbia - Okanagan;
  • Dr. Zach Walsh, University of British Columbia – Okanagan

2:45 pm – 3:15 pm

Refreshment Break

3:15 pm – 4:35 pm

Keynote Presentation #4

Spirit in Science—Traditional and Indigenous Perspectives on Healing Trauma with Psychedelic Plant Medicines

  • Dr. Joseph Tafur, Modern Spirit and Ocotillo Center for Integrative Medicine, author of Fellowship of the River;
  • Susan Beaulieu, Red Lake Nation Anishinaabe and the University of Minnesota
  • Chief Derek Cook, Bloodvein First Nation (Manitoba, Canada)
  • Rainbow Lopez, Tohono O’odham Nation
  • Christine Diindiisi McCleave, Turtle Mountain Anishinaabe and University of Alaska Fairbanks

4:35 pm – 4:45 pm

Keynote Presentation Q and A

4:45 pm – 5:45 pm

Late Breaking Research Presentations (all topics) (3 x 15 minutes)

All topics (3 of 15 minutes)

Traditional medicine and cultural considerations

ID-LB213

What Ayahuasca and Shipibo Plant Medicine Taught Me About Healing the Roots of Racism

Authors:

  • Chaikuni Witan, NIhue Ras Centro Espirtual

Neuroscience and clinical applications

ID-LB202

Ibogaine and Acute Opioid Detoxification

Authors:

  • Dr. Alberto Sola, Clear Sky Recovery Cancun
  • Hirpal Hundial, Universal Ibogaine

Neuroscience and clinical applications
ID-LB209
Treatment response in psilocybin-assisted therapy is predicted by baseline neuroticism and mediated by mystical experience and emotional breakthrough

Authors:

  • Brandon Weiss, Imperial College
  • David Erritzoe, Imperial College London
  • Robin Carhart-Harris, University of California, San Francisco

5:45 pm - 6:00 pm

Closing Remarks

  • Bia Labate, Chacruna Institute for Psychedelic Plant Medicines (Virtual)

7:30 pm - 9:00 pm

Public Event

Psychedelic-Assisted Therapy - Facts & Fiction featuring some of the world’s top researchers in the field of psychedelic-assisted therapies and medicine

  • Dr. David Nutt, Imperial College London
  • Ifetayo Harvey, POC Psychedelic Collective
  • Dr. Dawn Davis, Native Sci CEO
  • Dr. Monnica Williams – School of Psychology, University of Ottawa
  • Dr. Olivia Marcus – New York University
  • Dr. Rick Doblin – MAPS
  • Moderator: Dr. Brian Rush, CAMH/University of Toronto

Sunday, May 29th, 2022

THEME:

Prevention and Treatment of Mental Health Disorders:
Part II: Public Health, Policy, and Regulatory Considerations

Master of Ceremonies: Stacia Butterfield

8:30 am – 8:45 am

Opening Remarks and Commentary on Challenges in Conducting Clinical Research with Schedule I Psychedelics: From the 1960s to the Present

  • Dr Katherine Bonson, U.S. Food and Drug Administration (Virtual)

8:45 am – 9:25 am

Keynote Presentation #5
Ketamine-Assisted Psychotherapy in North America: A Review and Commentary

  • Dr. Steven Rosonke, Rainfall Medicine
  • Dr. Devon Christie, Numinus Wellness and UBC Family Medicine 
  • Discussant: Dr. Dominique Morisano

9:25 am – 9:45 am

Keynote Presentation Q and A

9:45 am – 10:30 am

Poster Viewing and Refreshment Break

ID

Poster Title

Presenter

LB206

A New Path for Hope: Therapeutic Potential of 5-MeO-DMT – from Nature, to Synthesis, to Health Equity

Robert Kargbo

16

A Study Design for a Pragmatic, Open-Label, Phase 2 Study of Psilocybin-Research Intervention with Motivational Enhancement for Substance Use Disorders (PRIME-SUD)"

Lindsay Mackay

119

Accounting for the Clinical Efficacy of Psychedelic Therapies: How to Reconcile Mysticism and the Scientific Worldview?

Tuomas Pernu

88

Alcohol use, mental health outcomes, and psychedelic use: do mystical experiences matter?

Tashia Petker

15

Clinical applications of attachment theory in psychedelic-assisted therapy for substance use disorder

Aaron Cherniak

LB210

Computationally defined suicidality subtypes and their differential response to psilocybin vs ketamine therapy

Povilas Karvelis

64

Design and Rationale for an Open-Label Clinical Trial to Evaluate the Feasibility, Clinical Effects, and Safety of Psilocybin-Assisted Psychotherapy for Treatment- Body Dysmorphic Disorder and Treatment-Resistant Obsessive-Compulsive Disorder.

Nicole Ledwos

113

Development and Implementation of a Canadian Psilocybin-Assisted Therapy Training Program

Joshua Rosenblat

77

Entity Encounters on Psychedelics: An Active Inference Account of Spirits, Guides, and Invisible Presences

Jonas Mago

34

Examining the prevalence and impact of adverse life event re-experiencing during the ceremonial use of ayahuasca

Brandon Weiss

92

Examining the association between psychedelic use, mental health and the COVID-19 pandemic in young adults who use substances

Christopher Nelson

39

How the "we" helps heal the "me": psychedelic peer supports and communities of care

Amy Bartlett

7

Intranasal Ketamine in ECT Non-responders with Treatment Resistant Depression. Open Label Pilot Clinical Trial

Yuliya Knyahnytska

94

Ketamine for the treatment of mental health and substance use disorders: a comprehensive systematic review

Shannon Golsof

40

L'induction photonique des états de transe : une alternative efficace et élégante aux substances psychoactives en général

Alexandre Quaranta

102

Low-Dose Psycholytic Therapy: A Neglected Approach?

Torsten Passie

91

Mapping Psilocybin-assisted Therapy: A Scoping Review

Ron Shore

24

MDMA-assisted therapy: exploratory data demonstrates potential for chronic pain

Devon Christie

87

Novel Therapies for First Responders and Military Veterans

Jonathan Hill

74

Personalized medicine and psychedelics

Olga Chernoloz

73

Psilocybin as a Treatment for Anorexia Nervosa: Study Protocol and 6-Month Feasibility Update

Hannah Douglass

116

Psilocybin-assisted psychotherapy for Post-traumatic Stress Disorder in Veterans: a protocol description

Rakesh Jetly

LB212

Psychedelic Report Index: A Standardized Tool For Indexing and Tracking Subjective Reports of Psychedelic Associated Experiences

Marcos Ibrahim

72

Randomized, double-blind, placebo-controlled study assessing the efficacy of microdosed psilocybin on reducing depression and/or anxiety levels in adults.

Olga Chernoloz

111

Real World Effectiveness of Repeated Ketamine Infusions for Treatment Resistant Mood Disorders

Joshua Rosenblat

69

Right-Wing Psychedelia: Political Pluripotency and Ideology on Drugs

Brian Pace

66

Safety and Efficacy of Serotonergic Psychedelic Drugs for the Treatment of Anxiety Disorders and Obsessive-Compulsive Disorder: A Systematic Review

Jamie Hujan

42

Psychedelic interventions to alleviate psychological suffering at the end of life: Protocol for a scoping review

Sarah Kratina

18

The Condor and the Eagle: Integrating South and North Indigenous traditions

Michael Chaiton-Murray

112

The efficacy and tolerability of psilocybin in participants with treatment-resistant depression: a phase 2, randomized feasibility study

Joshua Rosenblat

127

The Relationship between Classic Psychedelics and Suicidality: A Systematic Review

Nikhita Singhal

56

Therapeutic Uses of Psychedelics for Eating Disorders and Body Image Disorders: A Narrative Review

Justyne Rodas

120

TRIP protocol for treatment resistant depression.

Tatiana Zdyb

10:30 am – 12:00pm

Peer-Reviewed Paper presentations

Peer-Reviewed Paper presentations focused on policy, public health, and regulatory issues (5 of 15 minutes)

ID-98

Abstract

The Need for Psychedelic-Assisted
Therapy in the Black Community
and the Burdens of its Provision

Authors

  • Dr. Sonya Faber, Bioville GmbH;
  • Dr. Darron Smith, The University of Memphis (Virtual)

ID-100

Abstract

Entheogens and Psychedelics in
Canada, Proposal for a New Paradigm: A Call for a National Advisory Council

Authors

  • Rev Dr. Jessica Rochester, Céu do Montreal;
  • Dr. Anne Vallely, University of Ottawa;
  • Dr. Monnica Williams, University of Ottawa;
  • Dr. Paul Grof, Mood Disorders Centre of Ottawa;
  • Kate Caldwell, Interaction Experience;
  • Dr. Harvey Chang, Jewish General Hospital

ID-58

Abstract

Psychedelics and the Commercial Determinants of Health: An Ethics
Case Study Analysis of Psychedelic
Industry-Healthcare Relationships

Authors

  • Dr. Daniel Buchman, Centre for Addiction and Mental Health

ID-76

Abstract

A grounded theory of online
community members’ self-reported
decision-making logic before their
first use of psychedelic self-treatment for depression and/or anxiety.

Authors

  • David Kryszajtys, University of Toronto;
  • Dr. Jacqueline Bender, University Health
    Network;
  • Dr. Brian Rush, Centre for Addiction and Mental Health;
  • Carol Strike, University of Toronto

ID-23

Abstract

From Research to Regulatory Negotiations to Reality

Authors

  • Dr. Rick Doblin, MAPS

12:00 pm – 1:00 pm

Lunch (onsite, included)

1:00 pm - 2:30 pm

Panel Presentation

World Regulatory and Policy Discussion: A Pathway Forward

  • Dr. Javier Muniz, U.S. Food and Drug Administration;
  • Dr. Jorge Julio Gonzalez Olvera, Director of Attention Models in Mental Health at the Secretariat of the Mexican Board of Mental Health;
  • Dr. Florence Butlen-Ducuing, European Medicines Agency (Virtual);
  • Drs. Jennifer Pelley and Daniel Keene, Health Canada (Virtual);
  • Moderator: Dr. Doris Payer, Canadian Centre on Substance Use and Addiction

2:30 pm - 3:15 pm

Closing Plenary

Psychedelics in mental health and addiction treatment

  • Dr. Matthew Johnson, Center for Psychedelic and Consciousness Research, Johns Hopkins University

3:15 pm – 3:30 pm

Closing Plenary Q and A

3:30 pm – 4:00 pm

Closing Prayer and Acknowledgements

  • Prayer by Elder Clayton Shirt, Plains Cree/Anishinaabe
  • Closing Remarks and Acknowledgements by R2R2022 Co-Founders Drs. Dominique Morisano (CAMH/University of Toronto/University of Ottawa) and Brian Rush (CAMH/University of Toronto)
Stay up to date with global research efforts.

Webinar series is co-hosted by the Evidence Exchange Network (EENet).

Scroll to Top

This website uses cookies to ensure you get the best experience on our website.